Contract analysis

I. Executive Summary The purpose of this memorandum is to provide Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") with a preliminary assessment of the merits, risks, and procedural strategy for filing a declaratory-judgment action against Vantage Medical Distribution, LLC ("Vantage") in the Superior Court of Massachusetts, Business Litigation Session. The action would seek a judicial declaration that Van

II. Background and Factual Summary A. The Parties Penterra Pharmaceuticals Corp. Penterra is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol PTRA, with its principal executive offices located at 400 Carnegie Center Drive, Suite 600, Princeton, New Jersey 08540. Penterra is a mid-cap specialty pharmaceutical company focused on three core therapeutic areas: oncology, rare dise

Section 2.1 — Grant of Exclusive Territory. Section 2.1 of the EDA provides: "Supplier hereby grants to Distributor the exclusive right to distribute the Products within the Territory, as defined in Exhibit A." Exhibit A — Territory Definition. Exhibit A to the EDA, titled "Territory," provides in its entirety: "The states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont (collectively, t

Section 2.3 — Limitation on Extra-Territorial Activity. Section 2.3 further reinforces the territorial boundary: "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." This provision presupposes that the Territory is a fixed, defined area and that any activity beyond that boundary requires a separate, affirmative, written authoriza

Section 13.1 — Amendments. The EDA contains a standard written-amendment clause: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties." This provision requires that any change to the Agreement — including, necessarily, any expansion of the Territory defined in Exhibit A — be memorialized in a written instrument bea

Section 14.8 — Entire Agreement / Integration Clause. Section 14.8 provides: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This is a broad integration clause that establishes the EDA, including Exhibit A, as the comp

Section 14.2 — Governing Law. The Agreement is governed by the laws of the Commonwealth of Massachusetts, without regard to conflicts-of-law principles.

Section 14.5 — Dispute Resolution / Forum Selection. Section 14.5 provides for the exclusive jurisdiction of state or federal courts located in the Commonwealth of Massachusetts for any disputes arising out of or relating to the Agreement.

Section 5.2 — Minimum Annual Purchase Commitment. Section 5.2 establishes a minimum annual purchase commitment for Oncalaris® of $9.5 million per year at wholesale acquisition cost ("WAC"). This commitment provides context for evaluating Vantage's purchase volumes and its financial dependence on the Penterra relationship. C. Oncalaris® Revenue Significance Oncalaris® is Penterra's flagship oncology product. It is a n

III. Legal Analysis A. Declaratory-Judgment Jurisdiction and Ripeness Massachusetts General Laws chapter 231A authorizes courts to render declaratory judgments in cases involving actual controversies between parties. Section 1 of the statute provides that any person whose rights, duties, status, or other legal relations "are affected by a statute, municipal ordinance, by-law, or rule" or by a contract or other instru

1. Plain Language of Exhibit A The starting point for any contract-interpretation analysis under Massachusetts law is the language of the agreement itself. Massachusetts courts have consistently held that where contractual language is clear and unambiguous, the court must enforce the contract according to its plain terms and may not consider extrinsic evidence to vary or contradict those terms. The plain-meaning rule

Section 2.3 of the EDA further reinforces the plain meaning of the territorial limitation. By providing that "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent," Section 2.3 establishes three critical principles: (i) the Territory is a fixed boundary beyond which the Distributor's rights do not extend; (ii) activity outside the T

2. The Kapoor Email Does Not Constitute "Prior Written Consent" Under Section 2.3 Vantage's principal argument is that the Kapoor Email of January 12, 2018 constitutes "prior written consent" under Section 2.3, thereby authorizing Vantage to distribute Oncalaris® outside the Territory. This argument is unpersuasive for several independent reasons. First, the language of the Kapoor Email is plainly aspirational and fo

3. The Written-Amendment Requirement (Section 13.1) Bars Implied Modification Even if Vantage could point to some agreement — whether the Kapoor Email, a course of dealing, or oral discussions — to expand the Territory, Section 13.1 of the EDA precludes any such modification from being effective. Section 13.1 provides: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless

4. The Integration Clause (Section 14.8) Reinforces the Territorial Limitation

Section 14.8 of the EDA provides: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This is a broad and unqualified integration clause. Its effect is twofold. First, it establishes the EDA and its Exhibits — including Ex

1. Breach of Contract ($35 Million Claim) Vantage's breach-of-contract theory, as we understand it, is that Penterra's appointment of a competing tri-state distributor (Meridian) would violate Vantage's exclusive distribution rights under Section 2.1 of the EDA. The theory necessarily requires Vantage to establish that the "Territory" as defined in the Agreement includes New York, New Jersey, and Pennsylvania — becau

2. Breach of Implied Covenant of Good Faith and Fair Dealing Vantage may also assert a counterclaim for breach of the implied covenant of good faith and fair dealing. The theory would likely be that Penterra acted in bad faith by encouraging Vantage to invest in tri-state distribution infrastructure (through the Kapoor Email and subsequent interactions) and then refusing to acknowledge the territorial expansion — the

3. Promissory Estoppel Finally, Vantage may assert a promissory-estoppel counterclaim, arguing that it relied on the Kapoor Email and Penterra's acquiescence in making substantial investments in tri-state distribution infrastructure (e.g., hiring sales personnel, establishing customer relationships, incurring warehousing and logistics costs). Assessment. Under Massachusetts law, promissory estoppel requires three ele

IV. Recommended Forum and Procedural Strategy Forum. We recommend filing the Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County. Section 14.5 of the EDA provides for the exclusive jurisdiction of state or federal courts in Massachusetts, and the BLS is the appropriate session for this complex commercial contract dispute. The BLS offers experienced ju

V. Risk Assessment Probability of Success on Declaratory Judgment: High. The plain language of Exhibit A is unambiguous. The Territory is defined as six specific states, and the tri-state area is not among them. The written-amendment clause (Section 13.1) and integration clause (Section 14.8) provide strong contractual defenses against any claim of informal modification. Massachusetts law, particularly the Cambridge

VI. Budget and Staffing Calderwood & Harkness proposes the following engagement team and budget framework for the declaratory-judgment action, consistent with the engagement letter dated March 29, 2021: Engagement Team: All billing rates are subject to the 7% discount negotiated in the engagement letter dated March 29, 2021. Additional resources, including contract attorneys for document review and paralegal support,

VII. Recommendation Based on the foregoing analysis, Calderwood & Harkness recommends that Penterra Pharmaceuticals Corp. file a Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, as soon as practicable. Our target filing date is the week of April 12, 2021, subject to Penterra's authorization and final review of the complaint. The merits of Penterra's position are

VIII. Next Steps We recommend the following action items, subject to Penterra's review and approval:

1. Authorization to File. Penterra to confirm authorization for Calderwood & Harkness to file the Complaint for Declaratory Judgment. We request authorization no later than April 7, 2021 to meet the target filing date.

2. Complaint Filing. Calderwood & Harkness to finalize and file the Complaint for Declaratory Judgment in the Superior Court of Massachusetts, Business Litigation Session, Suffolk County. Target filing: week of April 12, 2021. A draft complaint will be circulated to Ms. Chao for review by April 5, 2021.

3. Litigation Hold. Penterra to issue litigation hold notices to all relevant custodians immediately upon authorization, including but not limited to: Dr. Marcus Lindholm (CEO), Jennifer Chao (General Counsel), Steven Kapoor (VP, Commercial Operations), Rachel Mendez (Director of Distribution & Logistics), and relevant personnel in IT, commercial operations, finance, and legal who may possess documents or electronica

4. Meridian Notification. Penterra to inform Thomas Welliver of Meridian National Distributors, Inc. that litigation has been initiated to resolve the territorial dispute and that the term sheet execution is being held pending resolution. Penterra should reassure Meridian of its continued interest in the tri-state distribution arrangement while managing expectations regarding the timeline for finalization.

5. Insurance Notification. Penterra should consider whether to provide notice of the threatened counterclaims to the Company's directors' and officers' liability insurer (Atlantic Shield Insurance Co.) and/or commercial general liability insurer (Commonwealth Mutual Assurance Corp.). While the counterclaims are contract-based and may not trigger D&O or CGL coverage, timely notification is prudent to preserve potentia

6. Counterclaim Preparation. Calderwood & Harkness to prepare an answer to any counterclaims filed by Vantage and to develop a comprehensive discovery plan in anticipation of Vantage's response to the complaint. We will also begin drafting a preliminary discovery conference statement and proposed scheduling order for submission to the BLS. We are available to discuss this memorandum and the recommended course of acti

1. Exclusive Distribution Agreement dated July 1, 2017, between Penterra Pharmaceuticals Corp. and Vantage Medical Distribution, LLC (with Exhibit A — Territory Definition)

2. Email from Steven Kapoor to Donald Farnham, dated January 12, 2018 (the "Kapoor